microRNA‑22 acts as a metastasis suppressor by targeting metadherin in gastric cancer

Tang,Yunyun; Liu,Xiaoping; Su,Bo; Zhang,Zhiwei; Zeng,Xi; Lei,Yanping; Shan,Jian; Wu,Yongjun; Tang,Hailin; Su,Qi

doi:10.3892/mmr.2014.2682

microRNA‑22 acts as a metastasis suppressor by targeting metadherin in gastric cancer

Authors:
- Yunyun Tang
- Xiaoping Liu
- Bo Su
- Zhiwei Zhang
- Xi Zeng
- Yanping Lei
- Jian Shan
- Yongjun Wu
- Hailin Tang
- Qi Su
View Affiliations

Affiliations: Center for Gastric Cancer Research of Hunan Province, First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China, Sun Yat‑Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China, Cancer Research Institute, University of South China, Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, Hengyang, Hunan 421001, P.R. China
Published online on: October 16, 2014 https://doi.org/10.3892/mmr.2014.2682
Pages: 454-460

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNA (miR)‑22 has been reported to be downregulated in hepatocellular, lung, colorectal, ovarian and breast cancer, acting as a tumor suppressor. The present study investigated the potential effects of miR‑22 on gastric cancer invasion and metastasis and the molecular mechanism. miR‑22 expression was examined in tumor tissues of in 89 gastric cancer patients by in situ hybridization (ISH) analysis. Additionally, the association between miR‑22 levels and clinicopathological parameters was analyzed. A luciferase assay was conducted for target identification. The ability of invasion and metastasis of gastric cancer cells in vitro and in vivo was evaluated by cell migration and invasion assays and in a xenograft model. The results showed that miR‑22 was downregulated in the gastric cancer specimens and significantly correlated with the advanced clinical stage and lymph node metastasis. In addition, metadherin (MTDH) was shown to be a direct target of miR‑22 and the expression of MTDH was inversely correlated with miR‑22 expression in gastric cancer. Ectopic expression of miR‑22 suppressed cell invasion and metastasis in vitro and in vivo. The present study suggested that miR‑22 may be a valuable prognostic factor in gastric cancer. miR‑22 inhibited gastric cancer cell invasion and metastasis by directly targeting MTDH. The novel miR‑22/MTDH link confirmed in the present study provided a novel, potential therapeutic target for the treatment of gastric cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Coburn NG: Lymph nodes and gastric cancer. J Surg Oncol. 99:199–206. 2009. View Article : Google Scholar : PubMed/NCBI
3	Tang H, Liu X, Wang Z, et al: Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res. 1390:21–32. 2011. View Article : Google Scholar : PubMed/NCBI
4	Cheng CJ and Slack FJ: The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J. 18:232–237. 2012. View Article : Google Scholar : PubMed/NCBI
5	Tang H, Deng M, Tang Y, et al: miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clin Cancer Res. 19:5602–5612. 2013. View Article : Google Scholar : PubMed/NCBI
6	Zheng B, Liang L, Wang C, et al: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 17:7574–7583. 2011. View Article : Google Scholar : PubMed/NCBI
7	Liu D, Xia P, Diao D, et al: MiRNA-429 suppresses the growth of gastric cancer cells in vitro. J Biomed Res. 26:389–393. 2012. View Article : Google Scholar : PubMed/NCBI
8	He XP, Shao Y, Li XL, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J. 279:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhang L, Liu X, Jin H, et al: miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett. 332:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
10	Qin S, Ai F, Ji WF, Rao W, Zhang HC and Yao WJ: miR-19a promotes cell growth and tumorigenesis through targeting SOCS1 in gastric cancer. Asian Pac J Cancer Prev. 14:835–840. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wang M, Li C, Yu B, et al: Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. J Gastroenterol. 48:1023–1033. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wu W, Takanashi M, Borjigin N, et al: MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer. 108:653–661. 2013. View Article : Google Scholar : PubMed/NCBI
13	Yang ZX, Lu CY, Yang YL, Dou KF and Tao KS: MicroRNA- 125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells. Mol Med Rep. 7:229–232. 2013.PubMed/NCBI
14	Zhi Q, Guo X, Guo L, et al: Oncogenic miR-544 is an important molecular target in gastric cancer. Anticancer Agents Med Chem. 13:270–275. 2013. View Article : Google Scholar : PubMed/NCBI
15	Guo JX, Tao QS, Lou PR, Chen XC, Chen J and Yuan GB: miR-181b as a potential molecular target for anticancer therapy of gastric neoplasms. Asian Pac J Cancer Prev. 13:2263–2267. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tang H, Kong Y, Guo J, et al: Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Lett. 340:72–81. 2013. View Article : Google Scholar : PubMed/NCBI
17	Guo MM, Hu LH, Wang YQ, et al: miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1. Med Oncol. 30:5422013. View Article : Google Scholar : PubMed/NCBI
18	Li B, Song Y, Liu TJ, et al: miRNA-22 suppresses colon cancer cell migration and invasion by inhibiting the expression of T-cell lymphoma invasion and metastasis 1 and matrix metalloproteinases 2 and 9. Oncol Rep. 29:1932–1938. 2013.PubMed/NCBI
19	Ling B, Wang GX, Long G, Qiu JH and Hu ZL: Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol. 138:1355–1361. 2012. View Article : Google Scholar : PubMed/NCBI
20	Xiong J, Yu D, Wei N, et al: An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J. 277:1684–1694. 2010. View Article : Google Scholar
21	Wang W, Li F, Zhang Y, Tu Y, Yang Q and Gao X: Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol. 8:1022013. View Article : Google Scholar : PubMed/NCBI
22	Song SJ, Ito K, Ala U, et al: The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell. 13:87–101. 2013. View Article : Google Scholar : PubMed/NCBI
23	Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ and Fisher PB: Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene. 353:8–15. 2005. View Article : Google Scholar : PubMed/NCBI
24	Liu L, Wu J, Ying Z, et al: Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res. 70:3750–3759. 2010. View Article : Google Scholar : PubMed/NCBI
25	Ahn S, Hyeon J and Park CK: Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy. Gut Liver. 7:206–212. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wang N, Du X, Zang L, et al: Prognostic impact of Metadherin-SND1 interaction in colon cancer. Mol Biol Rep. 39:10497–10504. 2012. View Article : Google Scholar : PubMed/NCBI
27	Tokunaga E, Nakashima Y, Yamashita N, et al: Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer. 21:341–349. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhou J, Li J, Wang Z, Yin C and Zhang W: Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival. Asia Pac J Clin Oncol. 8:e42–e48. 2012. View Article : Google Scholar : PubMed/NCBI
29	Meng X, Brachova P, Yang S, et al: Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment. PLoS One. 6:e209202011. View Article : Google Scholar : PubMed/NCBI
30	Ge X, Lv X, Feng L, et al: Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma. PLoS One. 7:e394492012. View Article : Google Scholar : PubMed/NCBI
31	Zhang J, Zhang Y, Liu S, et al: Metadherin confers chemoresistance of cervical cancer cells by inducing autophagy and activating ERK/NF-κB pathway. Tumour Biol. 34:2433–2440. 2013.PubMed/NCBI
32	Hu G, Wei Y and Kang Y: The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res. 15:5615–5620. 2009. View Article : Google Scholar : PubMed/NCBI
33	Li X, Kong X, Huo Q, et al: Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci. 102:1151–1157. 2011. View Article : Google Scholar : PubMed/NCBI
34	Zhu K, Dai Z, Pan Q, et al: Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 17:7294–7302. 2011. View Article : Google Scholar